Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share option transaction and does not contain financial performance data.
Material Changes
The material change disclosed is the grant of share options to Mr. J S Heslop. On October 22, 2009, he was granted options over 933 ordinary shares at an exercise price of £9.72 per share under the GlaxoSmithKline UK Savings Related Share Option Plan. The company was advised of this transaction on October 30, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Transaction Details: Verify the grant of 933 options to Mr. J S Heslop at £9.72 per share.
- Plan Compliance: Confirm the transaction aligns with the GlaxoSmithKline UK Savings Related Share Option Plan.
- Reporting Timeline: Note the gap between the grant date (Oct 22, 2009), company notification (Oct 30, 2009), and filing date (Nov 2, 2009).